AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.
News|Slideshows|March 25, 2019
ACC.19: 3 Studies in Cardioprotection
Author(s)Veronica Hackethal, MD
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.
Advertisement
Advertisement
Related to this article
Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Advertisement
Advertisement
Trending on Patient Care Online
1
American Cancer Society Updates Prostate Cancer Screening Guidelines
2
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
3
Yoga-Based Cardiac Rehab Improves Quality of Life in Heart Failure Trial
4
Retatrutide Phase 3 Trials Report Reduced Knee Osteoarthritis Pain
5